Table 3.
Characteristics of the study population at cohort inclusion, stratified by those completing the third phase cross-sectional visit, deceased, and lost to follow-up with known or unknown vital status.
| Characteristics | Completed follow-up (n=147) | Deceaseda (n=42) | Lost to follow-up (n=119) | P valueb | ||||||||||
|
|
|
|
Known vital statusc (n=41) | Unknown vital status (n=78) |
|
|||||||||
| Male, n (%) | 119 (81.0) | 39 (92.9) | 35 (85.4) | 66 (84.6) | .32 | |||||||||
| Age (years), median (IQR) | 40 (35-44) | 44 (38-53) | 39 (34-41) | 38 (34-43) | .002 | |||||||||
| Alcohol consumption >1 glass per day (n=295), n (%) | 87 (61.3) | 22 (55.0) | 22 (55.0) | 45 (61.6) | .80 | |||||||||
| BMI (kg/m2; n=291), n (%) | .99 | |||||||||||||
| Underweight (16.5-18.5) | 8 (5.8) | 3 (7.5) | 1 (2.5) | 4 (5.6) |
|
|||||||||
| Normal (18.5-25.0) | 105 (75.5) | 31 (77.5) | 31 (77.5) | 54 (75.0) |
|
|||||||||
|
|
Overweight (25-30) | 23 (16.6) | 5 (12.5) | 7 (17.5) | 11 (15.3) |
|
||||||||
| Moderate or severe obesity (>30) | 3 (2.2) | 1 (2.5) | 1 (2.5) | 3 (4.2) |
|
|||||||||
| Estimated HIV infection duration (years), median (IQR) | 9.4 (3.8-13.1) | 13.1 (7.1-15.6) | 10.1 (2.8-14.6) | 9.4 (3.2-13.8) | .06 | |||||||||
| AIDS-defining illness, n (%) | 30 (20.4) | 21 (50.0) | 12 (29.3) | 16 (20.5) | .001 | |||||||||
| CD4+ T cell count (per mm3), median (IQR) | 404 (283-557) | 370 (249-474) | 411 (338-619) | 406 (268-562) | .65 | |||||||||
| Nadir CD4+ T cell count (per mm3; n=271), median (IQR) | 212 (107-309) | 128 (65-304) | 235 (172-346) | 238 (70-384) | .08 | |||||||||
| ARTd experienced at inclusion, n (%) | 122 (83.0) | 37 (88.1) | 31 (75.6) | 61 (79.2) | .45 | |||||||||
| Detectable HIV RNA (>50 copies/mL), n (%) | 64 (43.5) | 14 (34.2) | 22 (53.7) | 45 (57.7) | .05 | |||||||||
| HIV-RNA viral load (log10 copies/mL)e, median (IQR) | 3.91 (2.48-4.41) | 3.83 (2.59-4.05) | 3.99 (3.04-4.53) | 3.67 (2.87-4.46) | .89 | |||||||||
| From country of high endemicity, n (%) | 47 (32.0) | 4 (9.5) | 13 (31.7) | 22 (28.2) | .02 | |||||||||
| Estimated HBVf infection duration (years), median (IQR) | 7.3 (2.8-11.2) | 6.7 (2.3-13.5) | 5.5 (2.8-11.5) | 3.9 (1.7-8.9) | .04 | |||||||||
| HBV DNA >60 IU/mL, n (%) | 113 (76.9) | 31 (75.6) | 31 (75.6) | 62 (79.5) | .95 | |||||||||
| HBV-DNA viral load (log10 IU/mL)e, median (IQR) | 3.39 (2.36-6.58) | 4.63 (2.71-6.88) | 5.02 (2.28-6.58) | 4.54 (2.76-6.88) | .45 | |||||||||
| HBeAgg positive, n (%) | 73 (49.7) | 29 (69.0) | 20 (48.8) | 38 (48.7) | .13 | |||||||||
| HBV genotype (n=170), n (%) | .36 | |||||||||||||
| A | 51 (68.0) | 17 (60.7) | 13 (61.9) | 24 (52.2) |
|
|||||||||
|
|
B | 0 (0.0) | 0 (0.0) | 0 (0.0) | 1 (2.2) |
|
||||||||
| D | 7 (9.3) | 4 (14.3) | 2 (9.5) | 4 (8.7) |
|
|||||||||
|
|
E | 8 (10.7) | 1 (3.6) | 1 (4.8) | 9 (19.6) |
|
||||||||
| G | 5 (6.7) | 4 (14.3) | 4 (19.1) | 6 (13.0) |
|
|||||||||
| Mixed A/D or A/G | 4 (5.3) | 2 (7.1) | 1 (4.8) | 2 (4.3) |
|
|||||||||
| Precore W28stop mutation (n=164), n (%) | 18 (24.7) | 4 (15.4) | 7 (33.3) | 18 (40.9) | .10 | |||||||||
| Lamivudine-resistance mutations (n=146), n (%) | 42 (64.6) | 14 (66.7) | 14 (77.8) | 27 (64.3) | .80 | |||||||||
| Other viral hepatitis, n (%) | .31 | |||||||||||||
|
|
Anti-HCVh positive serology | 9 (6.1) | 2 (4.8) | 4 (9.8) | 4 (5.1) |
|
||||||||
|
|
Anti-HDVi positive serology | 6 (4.1) | 1 (2.4) | 3 (7.3) | 2 (2.6) |
|
||||||||
|
|
Anti-HCV and anti-HDV positive serology | 3 (2.0) | 5 (11.9) | 1 (2.4) | 3 (3.9) |
|
||||||||
aIncludes deaths observed during the study and from vital records.
bOverall significance between groups determined using the Kruskal-Wallis test for continuous variables and Pearson χ² test or Fisher exact test for categorical variables.
cIncludes patients whose vital status is known: 13 refusing to continue participation, 5 not proposed to continue follow-up, 1 transferred to a nonparticipating center before completing the third phase visit, 2 other or unknown reasons, and 22 with vital status determined by CépiDC.
dART: antiretroviral therapy.
eAmong patients with detectable viral loads.
fHBV: hepatitis B virus.
gHBeAg: hepatitis B e virus antigen.
hHCV: hepatitis C virus.
iHDV: hepatitis D virus.